MAIA Biotechnology, Inc. (MAIA)
- Previous Close
1.9100 - Open
1.8500 - Bid 2.1200 x 800
- Ask 2.1300 x 800
- Day's Range
1.8501 - 2.1500 - 52 Week Range
1.4000 - 5.9900 - Volume
272,418 - Avg. Volume
187,678 - Market Cap (intraday)
63.568M - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.14
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
maiabiotech.comRecent News: MAIA
View More
Performance Overview: MAIA
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAIA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAIA
View MoreValuation Measures
Market Cap
56.51M
Enterprise Value
46.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
15.55
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-119.61%
Return on Equity (ttm)
-1,131.02%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.25M
Diluted EPS (ttm)
-1.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
9.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.93M